|Bid||0.0000 x 900|
|Ask||0.0000 x 1400|
|Day's Range||4.9800 - 5.4600|
|52 Week Range||4.9800 - 33.9000|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.67|
MENLO PARK, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it will release financial results for the third quarter after market close on Monday, November 15, 2021. Talis will host a conference call, beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss financial and operational results. Interested parties ma
The big shareholder groups in Talis Biomedical Corporation ( NASDAQ:TLIS ) have power over the company. Insiders often...
LOS ANGELES, September 14, 2021--Glancy Prongay & Murray LLP ("GPM"), a national investor rights law firm, continues its investigation on behalf of Talis Biomedical Corporation ("Talis" or the "Company") (NASDAQ: TLIS) investors concerning the Company and its officers’ possible violations of the federal securities laws.